RNL Bio files new stem cell drug Ind with Kfda to initiate phase II and III cerebral palsy trials

RNL BIO CO LTD announced today the filing of an Investigational New Drug application with the Korean Food and Drug Administration to initiate clinical trials phase II and III assessing the company's RNL-Astrostem stem cell drug in patients with cerebral palsy .

http://www.news-medical.net/news/20130211/RNL-BIO-files-new-stem-cell-drug-IND-with-KFDA-to-initiate-phase-II-and-III-cerebral-palsy-trials.aspx